β-Hydroxy-β-Methylbutyrate Supplementation Promotes Antitumor Immunity in an Obesity Responsive Mouse Model of Pancreatic Ductal Adenocarcinoma

Authors

Michael F. Coleman, University of North Carolina
Kristyn A. Liu, University of Texas
Alexander J. Pfeil, University of North Carolina
Suhas K. Etigunta, University of North Carolina
Xiaohu Tang, Michigan Technical University
Salvador Fabela, University of North Carolina
et. al.

Document Type

Article

Publication Date

12-18-2021

Department

Department of Biological Sciences

Abstract

Pancreatic cancer (PDAC) is a deadly disease, exacerbated by obesity, which lacks effective therapeutic interventions. Most PDAC has a limited response to immune- and chemotherapy. Treating PDAC is made additionally challenging by the rapid emergence of muscle wasting and cachexia, which predict poor response to several therapies. We have found that dietary supplementation with β-hydroxy-β-methylbutyrate promotes immunosurveillance in PDAC tumors and protects muscle. This dietary supplement has the potential to be an important adjuvant in PDAC therapy, opening the doors to immunotherapy response.

Publisher's Statement

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Publisher’s version of record: https://doi.org/10.3390/cancers13246359

Publication Title

Cancers

Recommended Citation

Coleman, M. F., Liu, K. A., Pfeil, A. J., Etigunta, S. K., Tang, X., Fabela, S., & et. al. (2021). β-Hydroxy-β-Methylbutyrate Supplementation Promotes Antitumor Immunity in an Obesity Responsive Mouse Model of Pancreatic Ductal Adenocarcinoma. Cancers, 13(24). http://doi.org/10.3390/cancers13246359
Retrieved from: https://digitalcommons.mtu.edu/michigantech-p/15915

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Version

Publisher's PDF